S. Margaret Paik to Antineoplastic Combined Chemotherapy Protocols
This is a "connection" page, showing publications S. Margaret Paik has written about Antineoplastic Combined Chemotherapy Protocols.
Connection Strength
0.275
-
Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer. J Clin Oncol. 2024 May 01; 42(13):1520-1530.
Score: 0.100
-
NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2. J Clin Oncol. 2020 02 10; 38(5):444-453.
Score: 0.075
-
The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40. Ann Surg Oncol. 2017 Jul; 24(7):1853-1860.
Score: 0.061
-
Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive, Early-Stage Breast Cancer. J Clin Oncol. 2024 Sep 01; 42(25):3012-3021.
Score: 0.026
-
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2015 Nov 19; 373(21):2005-14.
Score: 0.014